Baxter International Inc.
Baxter International Inc. (BAX) Stock Competitors & Peer Comparison
See (BAX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BAX | $16.91 | -6.11% | 9B | -9.61 | -$1.81 | +2.09% |
| ISRG | $482.26 | +0.62% | 167.7B | 59.84 | $7.89 | N/A |
| BDX | $161.00 | +0.86% | 57.7B | 26.04 | $6.12 | +2.19% |
| BDXA | $59.24 | -2.24% | 55.9B | 21.44 | $2.76 | +2.19% |
| ALC | $77.67 | -1.06% | 37.7B | 39.04 | $1.98 | +0.43% |
| RMD | $231.85 | -0.24% | 33.7B | 22.83 | $10.11 | +1.01% |
| MDLN | $41.78 | +1.72% | 33.7B | 28.99 | $1.43 | N/A |
| WST | $239.70 | +3.73% | 17B | 34.68 | $6.79 | +0.36% |
| HOLX | $75.20 | -0.02% | 16.8B | 31.17 | $2.41 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.19% |
Stock Comparison
BAX vs ISRG Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, ISRG has a market cap of 167.7B. Regarding current trading prices, BAX is priced at $16.91, while ISRG trades at $482.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas ISRG's P/E ratio is 59.84. In terms of profitability, BAX's ROE is -0.14%, compared to ISRG's ROE of +0.16%. Regarding short-term risk, BAX is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check ISRG's competition here
BAX vs BDX Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, BDX has a market cap of 57.7B. Regarding current trading prices, BAX is priced at $16.91, while BDX trades at $161.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas BDX's P/E ratio is 26.04. In terms of profitability, BAX's ROE is -0.14%, compared to BDX's ROE of +0.07%. Regarding short-term risk, BAX is more volatile compared to BDX. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check BDX's competition here
BAX vs BDXA Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, BAX is priced at $16.91, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas BDXA's P/E ratio is 21.44. In terms of profitability, BAX's ROE is -0.14%, compared to BDXA's ROE of +0.07%. Regarding short-term risk, BAX is less volatile compared to BDXA. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check BDXA's competition here
BAX vs ALC Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, ALC has a market cap of 37.7B. Regarding current trading prices, BAX is priced at $16.91, while ALC trades at $77.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas ALC's P/E ratio is 39.04. In terms of profitability, BAX's ROE is -0.14%, compared to ALC's ROE of +0.04%. Regarding short-term risk, BAX is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check ALC's competition here
BAX vs RMD Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, RMD has a market cap of 33.7B. Regarding current trading prices, BAX is priced at $16.91, while RMD trades at $231.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas RMD's P/E ratio is 22.83. In terms of profitability, BAX's ROE is -0.14%, compared to RMD's ROE of +0.25%. Regarding short-term risk, BAX is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check RMD's competition here
BAX vs MDLN Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, MDLN has a market cap of 33.7B. Regarding current trading prices, BAX is priced at $16.91, while MDLN trades at $41.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas MDLN's P/E ratio is 28.99. In terms of profitability, BAX's ROE is -0.14%, compared to MDLN's ROE of +0.08%. Regarding short-term risk, BAX is more volatile compared to MDLN. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check MDLN's competition here
BAX vs WST Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, WST has a market cap of 17B. Regarding current trading prices, BAX is priced at $16.91, while WST trades at $239.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas WST's P/E ratio is 34.68. In terms of profitability, BAX's ROE is -0.14%, compared to WST's ROE of +0.17%. Regarding short-term risk, BAX is more volatile compared to WST. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check WST's competition here
BAX vs HOLX Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, HOLX has a market cap of 16.8B. Regarding current trading prices, BAX is priced at $16.91, while HOLX trades at $75.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas HOLX's P/E ratio is 31.17. In terms of profitability, BAX's ROE is -0.14%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, BAX is more volatile compared to HOLX. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check HOLX's competition here
BAX vs BDXB Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, BAX is priced at $16.91, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas BDXB's P/E ratio is 7.60. In terms of profitability, BAX's ROE is -0.14%, compared to BDXB's ROE of +0.07%. Regarding short-term risk, BAX is more volatile compared to BDXB. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check BDXB's competition here
BAX vs COO Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, COO has a market cap of 13.6B. Regarding current trading prices, BAX is priced at $16.91, while COO trades at $71.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas COO's P/E ratio is 35.14. In terms of profitability, BAX's ROE is -0.14%, compared to COO's ROE of +0.05%. Regarding short-term risk, BAX is more volatile compared to COO. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check COO's competition here
BAX vs MASI Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, BAX is priced at $16.91, while MASI trades at $175.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas MASI's P/E ratio is 45.82. In terms of profitability, BAX's ROE is -0.14%, compared to MASI's ROE of -0.17%. Regarding short-term risk, BAX is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check MASI's competition here
BAX vs ATR Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, ATR has a market cap of 8.4B. Regarding current trading prices, BAX is priced at $16.91, while ATR trades at $129.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas ATR's P/E ratio is 21.84. In terms of profitability, BAX's ROE is -0.14%, compared to ATR's ROE of +0.15%. Regarding short-term risk, BAX is more volatile compared to ATR. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check ATR's competition here
BAX vs RGEN Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, RGEN has a market cap of 6.4B. Regarding current trading prices, BAX is priced at $16.91, while RGEN trades at $115.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas RGEN's P/E ratio is 132.79. In terms of profitability, BAX's ROE is -0.14%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, BAX is more volatile compared to RGEN. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check RGEN's competition here
BAX vs BLCO Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, BLCO has a market cap of 5.7B. Regarding current trading prices, BAX is priced at $16.91, while BLCO trades at $16.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas BLCO's P/E ratio is -15.89. In terms of profitability, BAX's ROE is -0.14%, compared to BLCO's ROE of -0.06%. Regarding short-term risk, BAX is more volatile compared to BLCO. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check BLCO's competition here
BAX vs AVTR Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, AVTR has a market cap of 5.4B. Regarding current trading prices, BAX is priced at $16.91, while AVTR trades at $7.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas AVTR's P/E ratio is -10.17. In terms of profitability, BAX's ROE is -0.14%, compared to AVTR's ROE of -0.09%. Regarding short-term risk, BAX is less volatile compared to AVTR. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check AVTR's competition here
BAX vs TFX Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, TFX has a market cap of 4.7B. Regarding current trading prices, BAX is priced at $16.91, while TFX trades at $109.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas TFX's P/E ratio is 81.90. In terms of profitability, BAX's ROE is -0.14%, compared to TFX's ROE of -0.24%. Regarding short-term risk, BAX is more volatile compared to TFX. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check TFX's competition here
BAX vs MMSI Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, MMSI has a market cap of 4.2B. Regarding current trading prices, BAX is priced at $16.91, while MMSI trades at $69.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas MMSI's P/E ratio is 32.84. In terms of profitability, BAX's ROE is -0.14%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, BAX is more volatile compared to MMSI. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check MMSI's competition here
BAX vs STVN Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, STVN has a market cap of 4.1B. Regarding current trading prices, BAX is priced at $16.91, while STVN trades at $15.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas STVN's P/E ratio is 25.39. In terms of profitability, BAX's ROE is -0.14%, compared to STVN's ROE of +0.10%. Regarding short-term risk, BAX is more volatile compared to STVN. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check STVN's competition here
BAX vs ICUI Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, ICUI has a market cap of 3.1B. Regarding current trading prices, BAX is priced at $16.91, while ICUI trades at $126.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas ICUI's P/E ratio is 4195.00. In terms of profitability, BAX's ROE is -0.14%, compared to ICUI's ROE of +0.00%. Regarding short-term risk, BAX is more volatile compared to ICUI. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check ICUI's competition here
BAX vs WRBY Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, WRBY has a market cap of 2.9B. Regarding current trading prices, BAX is priced at $16.91, while WRBY trades at $23.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas WRBY's P/E ratio is 2405.00. In terms of profitability, BAX's ROE is -0.14%, compared to WRBY's ROE of +0.00%. Regarding short-term risk, BAX is less volatile compared to WRBY. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check WRBY's competition here
BAX vs HAE Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, HAE has a market cap of 2.8B. Regarding current trading prices, BAX is priced at $16.91, while HAE trades at $59.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas HAE's P/E ratio is 16.50. In terms of profitability, BAX's ROE is -0.14%, compared to HAE's ROE of +0.20%. Regarding short-term risk, BAX is more volatile compared to HAE. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check HAE's competition here
BAX vs LMAT Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, LMAT has a market cap of 2.5B. Regarding current trading prices, BAX is priced at $16.91, while LMAT trades at $110.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas LMAT's P/E ratio is 42.88. In terms of profitability, BAX's ROE is -0.14%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, BAX is more volatile compared to LMAT. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check LMAT's competition here
BAX vs XRAY Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, XRAY has a market cap of 2.3B. Regarding current trading prices, BAX is priced at $16.91, while XRAY trades at $11.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas XRAY's P/E ratio is -3.85. In terms of profitability, BAX's ROE is -0.14%, compared to XRAY's ROE of -0.35%. Regarding short-term risk, BAX is more volatile compared to XRAY. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check XRAY's competition here
BAX vs ATRC Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, ATRC has a market cap of 1.5B. Regarding current trading prices, BAX is priced at $16.91, while ATRC trades at $30.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas ATRC's P/E ratio is -124.35. In terms of profitability, BAX's ROE is -0.14%, compared to ATRC's ROE of -0.02%. Regarding short-term risk, BAX is more volatile compared to ATRC. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check ATRC's competition here
BAX vs PLSE Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, PLSE has a market cap of 1.5B. Regarding current trading prices, BAX is priced at $16.91, while PLSE trades at $22.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas PLSE's P/E ratio is -19.97. In terms of profitability, BAX's ROE is -0.14%, compared to PLSE's ROE of -0.73%. Regarding short-term risk, BAX is less volatile compared to PLSE. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check PLSE's competition here
BAX vs NVCR Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, NVCR has a market cap of 1.4B. Regarding current trading prices, BAX is priced at $16.91, while NVCR trades at $12.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas NVCR's P/E ratio is -9.89. In terms of profitability, BAX's ROE is -0.14%, compared to NVCR's ROE of -0.39%. Regarding short-term risk, BAX is more volatile compared to NVCR. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check NVCR's competition here
BAX vs QDEL Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, QDEL has a market cap of 1.2B. Regarding current trading prices, BAX is priced at $16.91, while QDEL trades at $17.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas QDEL's P/E ratio is -1.02. In terms of profitability, BAX's ROE is -0.14%, compared to QDEL's ROE of -0.46%. Regarding short-term risk, BAX is less volatile compared to QDEL. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check QDEL's competition here
BAX vs KMTS Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, KMTS has a market cap of 1.1B. Regarding current trading prices, BAX is priced at $16.91, while KMTS trades at $19.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas KMTS's P/E ratio is -4.82. In terms of profitability, BAX's ROE is -0.14%, compared to KMTS's ROE of -1.89%. Regarding short-term risk, BAX is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check KMTS's competition here
BAX vs AZTA Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, AZTA has a market cap of 986.6M. Regarding current trading prices, BAX is priced at $16.91, while AZTA trades at $20.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas AZTA's P/E ratio is 36.93. In terms of profitability, BAX's ROE is -0.14%, compared to AZTA's ROE of -0.03%. Regarding short-term risk, BAX is less volatile compared to AZTA. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check AZTA's competition here
BAX vs STAA Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, STAA has a market cap of 932.8M. Regarding current trading prices, BAX is priced at $16.91, while STAA trades at $18.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas STAA's P/E ratio is -11.63. In terms of profitability, BAX's ROE is -0.14%, compared to STAA's ROE of -0.23%. Regarding short-term risk, BAX is less volatile compared to STAA. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check STAA's competition here
BAX vs NNNN Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, NNNN has a market cap of 919.5M. Regarding current trading prices, BAX is priced at $16.91, while NNNN trades at $21.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas NNNN's P/E ratio is 349.17. In terms of profitability, BAX's ROE is -0.14%, compared to NNNN's ROE of +0.11%. Regarding short-term risk, BAX is more volatile compared to NNNN. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check NNNN's competition here
BAX vs BLFS Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, BLFS has a market cap of 884M. Regarding current trading prices, BAX is priced at $16.91, while BLFS trades at $19.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas BLFS's P/E ratio is -48.32. In terms of profitability, BAX's ROE is -0.14%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, BAX is more volatile compared to BLFS. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check BLFS's competition here
BAX vs ATRI Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, BAX is priced at $16.91, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas ATRI's P/E ratio is 64.50. In terms of profitability, BAX's ROE is -0.14%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, BAX is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check ATRI's competition here
BAX vs ANGO Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, ANGO has a market cap of 436.9M. Regarding current trading prices, BAX is priced at $16.91, while ANGO trades at $10.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas ANGO's P/E ratio is -15.82. In terms of profitability, BAX's ROE is -0.14%, compared to ANGO's ROE of -0.15%. Regarding short-term risk, BAX is more volatile compared to ANGO. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check ANGO's competition here
BAX vs OSUR Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, OSUR has a market cap of 217.2M. Regarding current trading prices, BAX is priced at $16.91, while OSUR trades at $3.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas OSUR's P/E ratio is -3.16. In terms of profitability, BAX's ROE is -0.14%, compared to OSUR's ROE of -0.19%. Regarding short-term risk, BAX is more volatile compared to OSUR. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check OSUR's competition here
BAX vs UTMD Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, UTMD has a market cap of 202.7M. Regarding current trading prices, BAX is priced at $16.91, while UTMD trades at $64.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas UTMD's P/E ratio is 18.18. In terms of profitability, BAX's ROE is -0.14%, compared to UTMD's ROE of +0.10%. Regarding short-term risk, BAX is more volatile compared to UTMD. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check UTMD's competition here
BAX vs KRMD Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, KRMD has a market cap of 198.3M. Regarding current trading prices, BAX is priced at $16.91, while KRMD trades at $4.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas KRMD's P/E ratio is -53.50. In terms of profitability, BAX's ROE is -0.14%, compared to KRMD's ROE of -0.16%. Regarding short-term risk, BAX is less volatile compared to KRMD. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check KRMD's competition here
BAX vs INFU Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, INFU has a market cap of 190M. Regarding current trading prices, BAX is priced at $16.91, while INFU trades at $9.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas INFU's P/E ratio is 30.15. In terms of profitability, BAX's ROE is -0.14%, compared to INFU's ROE of +0.12%. Regarding short-term risk, BAX is less volatile compared to INFU. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check INFU's competition here
BAX vs STXS Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, STXS has a market cap of 176.9M. Regarding current trading prices, BAX is priced at $16.91, while STXS trades at $1.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas STXS's P/E ratio is -6.77. In terms of profitability, BAX's ROE is -0.14%, compared to STXS's ROE of -1.92%. Regarding short-term risk, BAX is more volatile compared to STXS. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check STXS's competition here
BAX vs SMTI Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, SMTI has a market cap of 174.1M. Regarding current trading prices, BAX is priced at $16.91, while SMTI trades at $19.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas SMTI's P/E ratio is -27.06. In terms of profitability, BAX's ROE is -0.14%, compared to SMTI's ROE of -1.28%. Regarding short-term risk, BAX is more volatile compared to SMTI. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check SMTI's competition here
BAX vs PDEX Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, PDEX has a market cap of 158.1M. Regarding current trading prices, BAX is priced at $16.91, while PDEX trades at $48.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas PDEX's P/E ratio is 14.21. In terms of profitability, BAX's ROE is -0.14%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, BAX is less volatile compared to PDEX. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check PDEX's competition here
BAX vs MBOT Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, MBOT has a market cap of 122.6M. Regarding current trading prices, BAX is priced at $16.91, while MBOT trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas MBOT's P/E ratio is -5.98. In terms of profitability, BAX's ROE is -0.14%, compared to MBOT's ROE of -0.37%. Regarding short-term risk, BAX is less volatile compared to MBOT. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check MBOT's competition here
BAX vs NYXH Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, NYXH has a market cap of 117.3M. Regarding current trading prices, BAX is priced at $16.91, while NYXH trades at $3.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas NYXH's P/E ratio is -1.21. In terms of profitability, BAX's ROE is -0.14%, compared to NYXH's ROE of -1.01%. Regarding short-term risk, BAX is more volatile compared to NYXH. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check NYXH's competition here
BAX vs ZTEK Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, ZTEK has a market cap of 67.5M. Regarding current trading prices, BAX is priced at $16.91, while ZTEK trades at $0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas ZTEK's P/E ratio is -10.47. In terms of profitability, BAX's ROE is -0.14%, compared to ZTEK's ROE of -0.61%. Regarding short-term risk, BAX is less volatile compared to ZTEK. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check ZTEK's competition here
BAX vs AKYA Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, BAX is priced at $16.91, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas AKYA's P/E ratio is -1.34. In terms of profitability, BAX's ROE is -0.14%, compared to AKYA's ROE of -6.72%. Regarding short-term risk, BAX is more volatile compared to AKYA. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check AKYA's competition here
BAX vs DXR Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, DXR has a market cap of 57.8M. Regarding current trading prices, BAX is priced at $16.91, while DXR trades at $11.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas DXR's P/E ratio is 7.00. In terms of profitability, BAX's ROE is -0.14%, compared to DXR's ROE of +0.22%. Regarding short-term risk, BAX is less volatile compared to DXR. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check DXR's competition here
BAX vs STSS Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, STSS has a market cap of 55.1M. Regarding current trading prices, BAX is priced at $16.91, while STSS trades at $1.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas STSS's P/E ratio is N/A. In terms of profitability, BAX's ROE is -0.14%, compared to STSS's ROE of -0.91%. Regarding short-term risk, BAX is less volatile compared to STSS. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check STSS's competition here
BAX vs OMIC Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, BAX is priced at $16.91, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas OMIC's P/E ratio is -0.58. In terms of profitability, BAX's ROE is -0.14%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, BAX is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check OMIC's competition here
BAX vs IGAP Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, BAX is priced at $16.91, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas IGAP's P/E ratio is -10.52. In terms of profitability, BAX's ROE is -0.14%, compared to IGAP's ROE of +1.21%. Regarding short-term risk, BAX is more volatile compared to IGAP. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check IGAP's competition here
BAX vs NEPH Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, NEPH has a market cap of 37.2M. Regarding current trading prices, BAX is priced at $16.91, while NEPH trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas NEPH's P/E ratio is 25.00. In terms of profitability, BAX's ROE is -0.14%, compared to NEPH's ROE of +0.12%. Regarding short-term risk, BAX is less volatile compared to NEPH. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check NEPH's competition here
BAX vs POCI Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, POCI has a market cap of 33M. Regarding current trading prices, BAX is priced at $16.91, while POCI trades at $4.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas POCI's P/E ratio is -4.60. In terms of profitability, BAX's ROE is -0.14%, compared to POCI's ROE of -0.61%. Regarding short-term risk, BAX is less volatile compared to POCI. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check POCI's competition here
BAX vs SDC Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, BAX is priced at $16.91, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas SDC's P/E ratio is -0.03. In terms of profitability, BAX's ROE is -0.14%, compared to SDC's ROE of -1.96%. Regarding short-term risk, BAX is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check SDC's competition here
BAX vs EKSO Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, EKSO has a market cap of 28M. Regarding current trading prices, BAX is priced at $16.91, while EKSO trades at $11.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas EKSO's P/E ratio is -2.35. In terms of profitability, BAX's ROE is -0.14%, compared to EKSO's ROE of -1.11%. Regarding short-term risk, BAX is less volatile compared to EKSO. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check EKSO's competition here
BAX vs IVC Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, BAX is priced at $16.91, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas IVC's P/E ratio is -0.79. In terms of profitability, BAX's ROE is -0.14%, compared to IVC's ROE of -0.46%. Regarding short-term risk, BAX is less volatile compared to IVC. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check IVC's competition here
BAX vs MLSS Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, MLSS has a market cap of 23.1M. Regarding current trading prices, BAX is priced at $16.91, while MLSS trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas MLSS's P/E ratio is -3.26. In terms of profitability, BAX's ROE is -0.14%, compared to MLSS's ROE of -1.65%. Regarding short-term risk, BAX is less volatile compared to MLSS. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check MLSS's competition here
BAX vs HBIO Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, HBIO has a market cap of 21.2M. Regarding current trading prices, BAX is priced at $16.91, while HBIO trades at $5.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas HBIO's P/E ratio is -0.39. In terms of profitability, BAX's ROE is -0.14%, compared to HBIO's ROE of -3.89%. Regarding short-term risk, BAX is less volatile compared to HBIO. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check HBIO's competition here
BAX vs RVP Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, RVP has a market cap of 21.1M. Regarding current trading prices, BAX is priced at $16.91, while RVP trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas RVP's P/E ratio is -3.20. In terms of profitability, BAX's ROE is -0.14%, compared to RVP's ROE of -0.08%. Regarding short-term risk, BAX is less volatile compared to RVP. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check RVP's competition here
BAX vs ZJYL Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, ZJYL has a market cap of 19.4M. Regarding current trading prices, BAX is priced at $16.91, while ZJYL trades at $2.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas ZJYL's P/E ratio is 12.40. In terms of profitability, BAX's ROE is -0.14%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, BAX is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check ZJYL's competition here
BAX vs FEMY Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, FEMY has a market cap of 16.7M. Regarding current trading prices, BAX is priced at $16.91, while FEMY trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas FEMY's P/E ratio is -0.82. In terms of profitability, BAX's ROE is -0.14%, compared to FEMY's ROE of -7.64%. Regarding short-term risk, BAX is less volatile compared to FEMY. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check FEMY's competition here
BAX vs RGNT Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, RGNT has a market cap of 12.9M. Regarding current trading prices, BAX is priced at $16.91, while RGNT trades at $3.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas RGNT's P/E ratio is -0.14. In terms of profitability, BAX's ROE is -0.14%, compared to RGNT's ROE of N/A. Regarding short-term risk, BAX is more volatile compared to RGNT. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check RGNT's competition here
BAX vs NXGL Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, NXGL has a market cap of 8.9M. Regarding current trading prices, BAX is priced at $16.91, while NXGL trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas NXGL's P/E ratio is -2.25. In terms of profitability, BAX's ROE is -0.14%, compared to NXGL's ROE of -0.55%. Regarding short-term risk, BAX is less volatile compared to NXGL. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check NXGL's competition here
BAX vs LUCY Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, LUCY has a market cap of 5.1M. Regarding current trading prices, BAX is priced at $16.91, while LUCY trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas LUCY's P/E ratio is -0.55. In terms of profitability, BAX's ROE is -0.14%, compared to LUCY's ROE of -0.82%. Regarding short-term risk, BAX is more volatile compared to LUCY. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check LUCY's competition here
BAX vs NSTG Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, BAX is priced at $16.91, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas NSTG's P/E ratio is -0.03. In terms of profitability, BAX's ROE is -0.14%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, BAX is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check NSTG's competition here
BAX vs NXGLW Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, NXGLW has a market cap of 3.9M. Regarding current trading prices, BAX is priced at $16.91, while NXGLW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas NXGLW's P/E ratio is -0.04. In terms of profitability, BAX's ROE is -0.14%, compared to NXGLW's ROE of -0.55%. Regarding short-term risk, BAX is less volatile compared to NXGLW. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check NXGLW's competition here
BAX vs MHUA Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, MHUA has a market cap of 2.7M. Regarding current trading prices, BAX is priced at $16.91, while MHUA trades at $8.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas MHUA's P/E ratio is 0.28. In terms of profitability, BAX's ROE is -0.14%, compared to MHUA's ROE of +0.06%. Regarding short-term risk, BAX is more volatile compared to MHUA. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check MHUA's competition here
BAX vs GMVD Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, BAX is priced at $16.91, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas GMVD's P/E ratio is -0.01. In terms of profitability, BAX's ROE is -0.14%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, BAX is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check GMVD's competition here
BAX vs GMVDW Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, BAX is priced at $16.91, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas GMVDW's P/E ratio is N/A. In terms of profitability, BAX's ROE is -0.14%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, BAX is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check GMVDW's competition here
BAX vs AVGR Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, BAX is priced at $16.91, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas AVGR's P/E ratio is -0.05. In terms of profitability, BAX's ROE is -0.14%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, BAX is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check AVGR's competition here
BAX vs POAI Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, POAI has a market cap of 1.4M. Regarding current trading prices, BAX is priced at $16.91, while POAI trades at $1.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas POAI's P/E ratio is -0.01. In terms of profitability, BAX's ROE is -0.14%, compared to POAI's ROE of +4.25%. Regarding short-term risk, BAX is less volatile compared to POAI. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check POAI's competition here
BAX vs GCTK Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, GCTK has a market cap of 700.8K. Regarding current trading prices, BAX is priced at $16.91, while GCTK trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas GCTK's P/E ratio is N/A. In terms of profitability, BAX's ROE is -0.14%, compared to GCTK's ROE of -26.59%. Regarding short-term risk, BAX is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check GCTK's competition here
BAX vs LUCYW Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, LUCYW has a market cap of 320.5K. Regarding current trading prices, BAX is priced at $16.91, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas LUCYW's P/E ratio is N/A. In terms of profitability, BAX's ROE is -0.14%, compared to LUCYW's ROE of -0.82%. Regarding short-term risk, BAX is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check LUCYW's competition here
BAX vs WOK Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, WOK has a market cap of 6.3K. Regarding current trading prices, BAX is priced at $16.91, while WOK trades at $1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas WOK's P/E ratio is N/A. In terms of profitability, BAX's ROE is -0.14%, compared to WOK's ROE of -0.07%. Regarding short-term risk, BAX is less volatile compared to WOK. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check WOK's competition here
BAX vs ARTC Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, ARTC has a market cap of 0. Regarding current trading prices, BAX is priced at $16.91, while ARTC trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas ARTC's P/E ratio is N/A. In terms of profitability, BAX's ROE is -0.14%, compared to ARTC's ROE of N/A. Regarding short-term risk, BAX is more volatile compared to ARTC. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check ARTC's competition here
BAX vs HRC Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, HRC has a market cap of 0. Regarding current trading prices, BAX is priced at $16.91, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas HRC's P/E ratio is 41.92. In terms of profitability, BAX's ROE is -0.14%, compared to HRC's ROE of +0.14%. Regarding short-term risk, BAX is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check HRC's competition here
BAX vs APR Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, APR has a market cap of 0. Regarding current trading prices, BAX is priced at $16.91, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas APR's P/E ratio is 22.59. In terms of profitability, BAX's ROE is -0.14%, compared to APR's ROE of +9.81%. Regarding short-term risk, BAX is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check APR's competition here
BAX vs IIN Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, IIN has a market cap of 0. Regarding current trading prices, BAX is priced at $16.91, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas IIN's P/E ratio is 226.45. In terms of profitability, BAX's ROE is -0.14%, compared to IIN's ROE of -0.00%. Regarding short-term risk, BAX is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check IIN's competition here
BAX vs ATRS Comparison March 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, BAX is priced at $16.91, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.61, whereas ATRS's P/E ratio is 14.95. In terms of profitability, BAX's ROE is -0.14%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, BAX is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check ATRS's competition here